ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Fundación Jiménez Díaz
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (10)
2023
-
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2692-2706
2021
-
Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Revista Espanola de Patologia, Vol. 54, Núm. 1, pp. 41-54
2020
-
Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 1976-1991
-
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
Cancer Medicine, Vol. 9, Núm. 3, pp. 1008-1016
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
2016
-
Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
Clinical and Translational Oncology, Vol. 18, Núm. 11, pp. 1072-1081
2015
-
Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2012
-
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 606-612